Chest dRain rEmoval intrAoperatively afTer thoracOscopic Wedge Resection

NCT05358158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2024-03-20

No results posted yet for this study

Summary

Chest drain is used routinely after lung surgery. Despite preliminary studies demonstrate the feasibility and safety of intraoperative chest drain removal, these are either retrospective or mainly concerning benign disease.

Hypothesis: Participants treated without post-operative chest tube after thoracoscopic wedge resection have less pain, reduced opioid usage without increasing postoperative complications than participants treated with standard post-operative chest tube, and could possibly be discharged earlier.

Conditions

  • Lung Neoplasms
  • Lung Surgery
  • Enhanced Recovery After Surgery
  • Fast-track Surgery
  • Pain
  • Opioid Use
  • Remission

Interventions

PROCEDURE

Intraoperative air leak test

A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.

PROCEDURE

Intraoperative chest drain removal

Chest drain is removed intraoperatively.

PROCEDURE

Standard chest drain placement

Chest drain is left in pleura.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER
  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • René H Petersen, MD, PhD · Rigshospitalet, Denmark

  • Thomas D Christensen, MD, PhD · Aarhus University Hospital

  • Bo L Holbek, MD, PhD · Rigshospitalet, Denmark

  • Morten Bendixen, MD, PhD · Aarhus University Hospital

  • Jonas J Rasmussen, MD · Aarhus University Hospital

  • Henrik Kehlet, MD, PhD · Rigshospitalet, Denmark

  • Henrik J Hansen, MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-04
Primary Completion
2024-03-17
Completion
2024-03-17

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05358158 on ClinicalTrials.gov